Article
Efficacy and Safety of Trametinib in Non-V600 BRAF Mutant Melanoma: A Phase II Study.
The oncologist - 1 Sept 2021
Nebhan Caroline A, Johnson Douglas B, Sullivan Ryan J, Amaria Roda N, Flaherty Keith T, Sosman Jeffrey A, Davies Michael A
Abstract excerpt
LESSONS LEARNED: This study suggests that trametinib has significant clinical activity in non-V600 BRAF mutation and BRAF fusion metastatic melanoma, albeit in a small cohort. All patients with metastatic melanoma should undergo sequencing of the BRAF gene to identify noncanonical BRAF mutations that may indicate benefit from treatment with trametinib. BACKGROUND: Non-V600 BRAF mutations and BRAF fusions in...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.